Ignyta, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Ignyta, Inc. – Product Pipeline Review – 2016’, provides an overview of the Ignyta, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ignyta, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Ignyta, Inc.

The report provides overview of Ignyta, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Ignyta, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Ignyta, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Ignyta, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ignyta, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ignyta, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Ignyta, Inc. Snapshot 5

Ignyta, Inc. Overview 5

Key Information 5

Key Facts 5

Ignyta, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Ignyta, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Ignyta, Inc. - Pipeline Products Glance 11

Ignyta, Inc. - Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Ignyta, Inc. - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Ignyta, Inc. - Drug Profiles 14

entrectinib 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

RXDX-105 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

taladegib 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

RXDX-106 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Small Molecules to Inhibit Protein kinase C-iota for Cancer 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Ignyta, Inc. - Pipeline Analysis 22

Ignyta, Inc. - Pipeline Products by Target 22

Ignyta, Inc. - Pipeline Products by Route of Administration 24

Ignyta, Inc. - Pipeline Products by Molecule Type 25

Ignyta, Inc. - Pipeline Products by Mechanism of Action 26

Ignyta, Inc. - Recent Pipeline Updates 28

Ignyta, Inc. - Dormant Projects 33

Ignyta, Inc. - Discontinued Pipeline Products 34

Discontinued Pipeline Product Profiles 34

RXDX-103 34

RXDX-104 34

RXDX-107 34

RXDX-108 34

Small Molecule 1 for Oncology 34

Small Molecule 2 for Oncology 35

Small Molecule 3 for Oncology 35

taladegib 35

Ignyta, Inc. - Locations And Subsidiaries 36

Head Office 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Ignyta, Inc., Key Information 5

Ignyta, Inc., Key Facts 5

Ignyta, Inc. – Pipeline by Indication, 2016 7

Ignyta, Inc. – Pipeline by Stage of Development, 2016 9

Ignyta, Inc. – Monotherapy Products in Pipeline, 2016 10

Ignyta, Inc. – Phase II, 2016 11

Ignyta, Inc. – Phase I, 2016 12

Ignyta, Inc. – Preclinical, 2016 13

Ignyta, Inc. – Pipeline by Target, 2016 22

Ignyta, Inc. – Pipeline by Route of Administration, 2016 24

Ignyta, Inc. – Pipeline by Molecule Type, 2016 25

Ignyta, Inc. – Pipeline Products by Mechanism of Action, 2016 26

Ignyta, Inc. – Recent Pipeline Updates, 2016 28

Ignyta, Inc. – Dormant Developmental Projects,2016 33

Ignyta, Inc. – Discontinued Pipeline Products, 2016 34

List of Figures

List of Figures

Ignyta, Inc. – Pipeline by Top 10 Indication, 2016 7

Ignyta, Inc. – Pipeline by Stage of Development, 2016 9

Ignyta, Inc. – Monotherapy Products in Pipeline, 2016 10

Ignyta, Inc. – Pipeline by Top 10 Target, 2016 22

Ignyta, Inc. – Pipeline by Route of Administration, 2016 24

Ignyta, Inc. – Pipeline by Molecule Type, 2016 25

Ignyta, Inc. – Pipeline Products by Mechanism of Action, 2016 26

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports